<DOC>
	<DOCNO>NCT00449202</DOCNO>
	<brief_summary>The purpose study evaluate safety , preliminary efficacy , pharmacokinetics two 14-day cycle escalate oral dos MP 101 100 obese adult subject .</brief_summary>
	<brief_title>Phase 2a Obesity Study Oral Doses Oleoyl-Estrone ( MP-101 )</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Oleoyl-estrone</mesh_term>
	<mesh_term>Estrone</mesh_term>
	<mesh_term>Estropipate</mesh_term>
	<criteria>Be male female age 18 65 year , inclusive Female subject must either surgically sterile least 2 year postmenopausal Have BMI 27 38.9 , inclusive Have stable weight past 30 day per subject report Be otherwise healthy acceptable medical history Have negative urinalysis test result drug abuse alcohol Have ability understand requirement study , provide write informed consent agree abide study restriction Exhibit stable behavior pattern regard smoke exercise Subject least one factor metabolic syndrome Be pregnant nursing Have take exclusionary medication past 30 day Have clinically significant abnormal laboratory test determine investigator Have clinically significant illness 30 day enrollment Have history test positive Hepatitis B virus , Hepatitis C virus , HIV Have confirm diagnosis history cancer , exception nonmelanoma skin cancer Have previous diagnosis diabetes Be otherwise unsuitable study , opinion investigator Have allergy safflower seed byproduct ( e.g. , safflower oil ) Have postmenopausal bleed within last 6 month Have involve formal informal ( selfimposed ) diet regimen within last 30 day Currently work night shift Have history know multiple miscarriage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2007</verification_date>
</DOC>